PROLIFERATIVE AND APOPTOTIC STATUS ON LYMPH NODE SECTIONS, INCLUDING THE PROLIFERATION CENTERS (PC), OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS

被引：0
|
作者：
Sachanas, S. [1 ]
Levidou, G. [2 ]
Angelopoulou, M. [3 ]
Moschogiannis, M. [2 ]
Yiakoumis, X. [2 ]
Vassilakopoulos, T. [3 ]
Kyrtsonis, M. C. [3 ]
Kontopidou, F. [3 ]
Kalpadakis, C. [4 ]
Tsirkinidis, P. [5 ]
Dimitriadou, E. [1 ]
Dimitrakopoulou, A. [6 ]
Kokoris, S. [7 ]
Panayiotidis, P. [3 ]
Papadaki, H. [4 ]
Patsouris, E. [3 ]
Korkolopoulou, P. [3 ]
Pangalis, G. [1 ]
机构：
[1] Athens Med Ctr, Phychikon Branch, Athens, Greece
[2] Athens Med Ctr, Athens, Greece
[3] Univ Athens, Athens, Greece
[4] Univ Crete, Haematol Dept, Iraklion, Greece
[5] 401 Mil Hosp, Athens, Greece
[6] Laikon Gen Hosp, Athens, Greece
[7] Attikon Gen Hosp, Athens, Greece
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0731
引用
收藏
页码：297 / 297
页数：1
相关论文
共 50 条
  • [41] High-dose therapy with stem cell support in 7 patients with chronic lymphocytic leukemia (CLL), pretreated with 2 or 3 lines of therapy including fludarabine
    Mahe, B
    Milpied, N
    Bulabois, CE
    JugeMorineau, N
    Moreau, P
    Harousseau, IL
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 318 - 318
  • [42] Model-based evaluation of the relationship between lymph node response and progression-free survival (PFS) in idelalisib-treated relapsed/refractory chronic lymphocytic leukemia (CLL)
    Daryani, Vinay M.
    Sharma, Shringi
    Xing, Guan
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S118 - S118
  • [43] Proliferation Centers in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Show Enhanced Expression of the Therapeutic Target PI3K and Other Targets of B-cell Receptor (BCR) Signaling
    Jain, Sarika
    Bullock, Grant C.
    Swerdlow, Steven H.
    Gibson, Sarah E.
    LABORATORY INVESTIGATION, 2016, 96 : 355A - 355A
  • [44] Proliferation Centers in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Show Enhanced Expression of the Therapeutic Target PI3K and Other Targets of B-cell Receptor (BCR) Signaling
    Jain, Sarika
    Bullock, Grant C.
    Swerdlow, Steven H.
    Gibson, Sarah E.
    MODERN PATHOLOGY, 2016, 29 : 355A - 355A
  • [45] Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study
    Jacobs, Ryan
    Jurczak, Wojciech
    Flinn, Ian W.
    Grosicki, Sebastian
    Giannopoulos, Krzysztof
    Wrobel, Tomasz
    Zafar, Syed F.
    Cultrera, Jennifer L.
    Kambhampati, Suman
    Danilov, Alexey V.
    Burke, John M.
    Goldschmidt, Jerome
    Beach, Douglas F.
    Huntington, Scott F.
    Ibarz, Javier Pinilla
    Sharman, Jeff P.
    Siddiqi, Tanya
    Brander, Danielle M.
    Shadman, Mazyar
    Page, John M.
    Dlugosz-Danecka, Monika
    Ghosh, Nilanjan
    Kolibaba, Kathryn S.
    Sportelli, Peter
    Miskin, Hari P.
    O'Connor, Owen A.
    Weiss, Michael S.
    Gribben, John G.
    BLOOD, 2021, 138 : 3726 - +
  • [46] Macrophage numbers in chronic lymphocytic leukemia lymph nodes diminish with disease stage in association with a skewing of the relative contribution of PAX5+B-cells to the proliferative component of the malignant node
    Cronin, Laura
    Birtwistle, Jane
    Roberts, Claudia
    Pratt, Guy
    Parry, Helen
    Di Maio, Alessandro
    Khanim, Farhat
    Rappoport, Joshua
    Drayson, Mark
    Bunce, Christopher
    Hayden, Rachel
    LEUKEMIA & LYMPHOMA, 2015, 56 : 3 - 5
  • [47] Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
    Gonzalez, David
    Martinez, Pilar
    Wade, Rachel
    Hockley, Sarah
    Oscier, David
    Matutes, Estella
    Dearden, Claire E.
    Richards, Sue M.
    Catovsky, Daniel
    Morgan, Gareth J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2223 - 2229
  • [48] The protein kinase inhibitor AG1801 abrogates constitutive STAT3 phosphorylation, suppresses colony-forming cell proliferation, and activates the apoptotic pathway in chronic lymphocytic leukemia (CLL).
    Ferrajoli, A
    Keating, MJ
    Van, Q
    Harris, DM
    Donato, NJ
    Priebe, W
    Kantarjian, HM
    Talpaz, M
    Levitzki, A
    Estrov, Z
    BLOOD, 2003, 102 (11) : 231A - 231A
  • [49] Different Pattern of CD154 and CD40 Expression On B-CLL and T Lymphocytes In Peripheral Blood, Bone Marrow and Lymph Node Microenvironment In B-Cell Chronic Lymphocytic Leukemia (B-CLL)
    Jaksic, Ozren
    Gizdic, Branimir
    Veic, Tajana Stoos
    Jaksic, Vlatka Pandzic
    Kusec, Rajko
    Pejsa, Vlatko
    Jaksic, Branimir
    BLOOD, 2010, 116 (21) : 1485 - 1485
  • [50] The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia (vol 58, pg 594, 2016)
    Vojdeman, F. J.
    van't Veer, M. B.
    Tjonnfjord, G. E.
    Itala-Remes, Maija
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 758 - 758
12345